A5023300925- Head and Neck Surgical Oncology
- Meningioma and schwannoma management
- Vascular Malformations Diagnosis and Treatment
- Nerve injury and regeneration
- Intracerebral and Subarachnoid Hemorrhage Research
- Axon Guidance and Neuronal Signaling
- Spinal Hematomas and Complications
- Neurofibromatosis and Schwannoma Cases
- Neurosurgical Procedures and Complications
Martin Luther University Halle-Wittenberg
2013-2017
Nimodipine is well characterized for the management of SAH (subarachnoid hemorrhage) and has been shown to promote a better outcome less DIND (delayed ischemic neurological deficits). In rat experiments, enhanced axonal sprouting higher survival motoneurons was demonstrated after cutting or crushing facial nerve by nimodipine. These results were confirmed in clinical trials following vestibular Schwannoma surgery. The mechanism protective competence nimodipine unknown. Therefore, this study,...
<b>Background and Study Aims/Object</b> Oral nimodipine improves neurologic outcome after aneurysmal subarachnoid hemorrhage. In addition, the neuroprotective efficacy of has been revealed following skull base, laryngeal, maxillofacial surgery. Pharmacokinetic investigations showed to reach higher serum levels parenteral versus enteral administration. Furthermore, a correlation between in serum, cerebrospinal fluid, nerve tissue could be quantified. These observations raise question whether...
Nimodipine is well characterized for the management of aneurysmal subarachnoid hemorrhage and has been shown to promote a better outcome less delayed ischemic neurological deficits. Animal clinical trials show neuroprotective efficacy following nerve injuries. We showed effect on Neuro2a cells. Subsequent microarray analysis revealed-among others-fatty acid 2-hydroxylase (FA2H) upregulated by nimodipine in vitro, which component myelin synthesis. Differentiated cells were analyzed...